Glycogen Synthase Kinase-3 Inhibition Induces Glioma Cell Death through c-MYC, Nuclear Factor-κB, and Glucose Regulation
- 12 August 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 68 (16), 6643-6651
- https://doi.org/10.1158/0008-5472.can-08-0850
Abstract
Glycogen synthase kinase 3 (GSK3), a serine/threonine kinase, is involved in diverse cellular processes ranging from nutrient and energy homeostasis to proliferation and apoptosis. Its role in glioblastoma multiforme has yet to be elucidated. We identified GSK3 as a regulator of glioblastoma multiforme cell survival using microarray analysis and small-molecule and genetic inhibitors of GSK3 activity. Various molecular and genetic approaches were then used to dissect out the molecular mechanisms responsible for GSK3 inhibition–induced cytotoxicity. We show that multiple small molecular inhibitors of GSK3 activity and genetic down-regulation of GSK3α/β significantly inhibit glioma cell survival and clonogenicity. The potency of the cytotoxic effects is directly correlated with decreased enzyme activity–activating phosphorylation of GSK3α/β Y276/Y216 and with increased enzyme activity inhibitory phosphorylation of GSK3α S21. Inhibition of GSK3 activity results in c-MYC activation, leading to the induction of Bax, Bim, DR4/DR5, and tumor necrosis factor-related apoptosis-inducing ligand expression and subsequent cytotoxicity. Additionally, down-regulation of GSK3 activity results in alteration of intracellular glucose metabolism resulting in dissociation of hexokinase II from the outer mitochondrial membrane with subsequent mitochondrial destabilization. Finally, inhibition of GSK3 activity causes a dramatic decrease in intracellular nuclear factor-κB activity. Inhibition of GSK3 activity results in c-MYC–dependent glioma cell death through multiple mechanisms, all of which converge on the apoptotic pathways. GSK3 may therefore be an important therapeutic target for gliomas. Future studies will further define the optimal combinations of GSK3 inhibitors and cytotoxic agents for use in gliomas and other cancers. [Cancer Res 2008;68(16):6643–51]Other Versions
This publication has 49 references indexed in Scilit:
- Direct Repression of FLIP Expression by c-myc Is a Major Determinant of TRAIL SensitivityMolecular and Cellular Biology, 2004
- Sensitization of human glioblastomas to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by NF-kappaB inhibitorsCancer Science, 2004
- In vitro and In vivo Activity of the Nuclear Factor-κB Inhibitor Sulfasalazine in Human GlioblastomasClinical Cancer Research, 2004
- The glamour and gloom of glycogen synthase kinase-3Trends in Biochemical Sciences, 2004
- Crossregulation of NF‐κB by the APC/GSK‐3β/β‐catenin pathwayMolecular Carcinogenesis, 2004
- Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation eventBiochemical Journal, 2004
- β-catenin interacts with and inhibits NF-κB in human colon and breast cancerCancer Cell, 2002
- Specificity and mechanism of action of some commonly used protein kinase inhibitorsBiochemical Journal, 2000
- Molecular changes during the genesis of human gliomasSeminars in Surgical Oncology, 1998
- Molecular Biology of Brain TumorsNeurosurgery, 1988